Intellia Receives FDA Lift on Clinical Hold for Nex-z Trials
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 02 2026
0mins
Source: Newsfilter
- Clinical Trial Advancement: Intellia Therapeutics announced that the FDA has lifted the clinical hold on its MAGNITUDE Phase 3 trial, allowing the continuation of research on nexiguran ziclumeran (nex-z) for patients with transthyretin amyloidosis with cardiomyopathy, marking a significant advancement in treatment development.
- Patient Safety Measures: To ensure patient safety, Intellia has aligned with the FDA to implement measures including enhanced monitoring of liver function and exclusion of patients with certain liver abnormalities, which will help mitigate potential risks and improve the likelihood of trial success.
- Trial Scale and Design: The MAGNITUDE trial aims to enroll approximately 1,200 patients using a randomized, double-blind, placebo-controlled design, primarily assessing a composite measure of cardiovascular-related events, which is expected to provide critical data support for the treatment of ATTR-CM.
- Market Potential: Based on CRISPR technology, if successful, nex-z could become the first one-time treatment for ATTR-CM, presenting significant market potential and substantially enhancing Intellia's competitiveness in the biopharmaceutical sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NTLA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NTLA
Wall Street analysts forecast NTLA stock price to rise
22 Analyst Rating
9 Buy
12 Hold
1 Sell
Moderate Buy
Current: 13.130
Low
4.00
Averages
16.50
High
54.00
Current: 13.130
Low
4.00
Averages
16.50
High
54.00
About NTLA
Intellia Therapeutics, Inc. is a clinical-stage gene editing company focused on developing medicine with CRISPR-based therapies and other core technologies. CRISPR/Cas9 is a gene editing technology that leverages the body’s natural processes to precisely edit DNA. The Company is developing lonvoguran ziclumeran (lonvo-z), referred to as NTLA-2002, for the treatment of hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) also referred to as NTLA-2001, for the treatment of transthyretin (ATTR) amyloidosis. It is focused on completing late-stage clinical development of its lead product candidates, lonvo-z for the treatment of patients with HAE and nex-z for the treatment of patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM) and hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). Its lead product candidates are the first in vivo genome editing product candidates into Phase III development. Its other pipeline products include REGV131-LNP1265 and AVC-201 & AVC-203.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Intellia Announces HAELO Clinical Trial Data Presentation
- Clinical Trial Data Presentation: Intellia Therapeutics will present data from the HAELO clinical trial at the 2026 EAACI Annual Congress, indicating the potential of its CRISPR gene editing therapy, lonvo-z, to revolutionize treatment standards for hereditary angioedema (HAE).
- Key Presentation Schedule: The company is set to deliver an oral presentation on June 13, showcasing results from a global randomized double-blind trial, which is expected to garner significant attention and enhance Intellia's market position.
- Poster Presentation Focus: Additionally, Intellia will present a poster detailing the treatment barriers faced by HAE patients in Europe, aiming to raise awareness of the condition and promote better treatment options, potentially fostering future collaborations and research.
- Regulatory Recognition: Lonvo-z has received five notable regulatory designations, including Orphan Drug and RMAT designations from the FDA, highlighting its innovative potential in HAE treatment and likely providing significant market opportunities and investor confidence for the company.
See More
Buffett's Investment Strategy and Healthcare Opportunities
- Investment Legacy: Warren Buffett has led Berkshire Hathaway to market-beating returns over 60 years by focusing on industries and companies with competitive advantages, and new CEO Greg Abel has pledged to continue this investment philosophy.
- Healthcare Sector Absence: Despite a diverse portfolio, Berkshire Hathaway is almost entirely absent from the healthcare sector, holding only kidney care giant DaVita, which Buffett added in 2011, while Abel closed the position in UnitedHealth Group in Q1 this year.
- Healthcare Investment Opportunities: The healthcare industry offers a wide range of investment options, with aggressive investors potentially targeting high-growth pharmaceutical companies like Eli Lilly, while conservative investors may prefer dividend-paying companies like Johnson & Johnson and Abbott Laboratories for steady earnings growth.
- Independent Investment Decisions: While it is valuable to follow the investment decisions of Buffett and Abel, investors should also consider the high-potential healthcare sector and make independent investment choices to capitalize on growth opportunities in this field.
See More
Buffett and Abel's Investment Strategies
- Investment Legacy: Warren Buffett has led Berkshire Hathaway to market-beating returns over the past sixty years, and new CEO Greg Abel promises to continue this successful path, demonstrating stability and continuity in the company's leadership.
- Portfolio Analysis: Berkshire Hathaway's largest holding is Apple, and although Buffett typically avoids tech stocks, he opened a position in Alphabet last year, with Abel increasing it in Q1 this year, indicating a cautious interest in the tech sector.
- Healthcare Sector Absence: Despite a diverse portfolio, the healthcare sector is almost entirely absent, with only DaVita added in 2011, and Abel closing the position in UnitedHealth Group in Q1, reflecting a potential missed growth opportunity in this vital industry.
- Independent Investor Thinking: While Buffett and Abel's investment strategies are worth following, investors should make independent decisions based on their own needs and resources, as the healthcare sector offers diverse investment opportunities, particularly in biotech and pharmaceuticals, which could yield significant returns.
See More
FDA Issues Draft Guidance to Accelerate Gene Therapy Development
- Draft Guidance Release: The FDA has issued a draft guidance aimed at accelerating the R&D process for gene and cell therapies by leveraging existing scientific and regulatory knowledge, which is expected to significantly enhance the approval efficiency of therapeutic products.
- Streamlined Regulatory Submissions: The guidance will clarify how sponsors can utilize publicly available information and established platform knowledge, including chemistry, manufacturing, and controls (CMC) data, to simplify regulatory submissions for human gene therapy products, thereby reducing compliance costs for companies.
- Early Engagement Recommendations: The FDA encourages companies to engage with it before submitting an IND application, including participating in Initial Targeted Engagement for Regulatory Advice on CBER/CDER Products (INTERACT) and pre-IND meetings, to ensure their development plans align with regulatory expectations, thus increasing their chances of success.
- Significant Industry Impact: The release of this draft guidance is likely to have a positive impact on leading gene and cell therapy biopharma companies, such as CRISPR Therapeutics and Intellia Therapeutics, potentially accelerating their product launch timelines and fostering overall industry growth.
See More
Intellia Reports Positive Phase 3 Data for Lonvo-z, Plans U.S. Launch in 2027
- Clinical Trial Success: Intellia's Phase 3 HAELO trial demonstrated that a single infusion of lonvo-z reduced HAE attacks by 87%, highlighting its potential as an innovative treatment that could significantly enhance patient quality of life.
- Regulatory Application Progress: The company has initiated a rolling Biologics License Application (BLA) for lonvo-z, with plans to complete the submission in the second half of 2026, which, if approved, will provide a unique treatment option for HAE patients and further solidify Intellia's leadership in gene editing.
- Strong Financial Position: As of March 31, 2026, Intellia reported $517.2 million in cash and cash equivalents, and with the $207 million raised from the public offering in April, the company expects to fund operations through at least 2028, ensuring the market launch of lonvo-z.
- Clinical Trials Resumed: Intellia has resumed patient screening for the MAGNITUDE and MAGNITUDE-2 trials of nex-z, with plans to complete patient enrollment in the second half of 2026, further advancing the treatment landscape for ATTR amyloidosis.
See More
Shopify and Others Tumble as Cathie Wood Buys on Dip
- Shopify Earnings Performance: Shopify reported a 34% revenue increase to $102.3 million in Q1, driven by a 35% rise in GMV, but a cautious outlook led to a 16% stock drop, indicating market concerns over its high valuation.
- Intellia's Positive Outlook: Intellia Therapeutics saw only a 4% decline, with Canaccord raising its price target from $48 to $58, reflecting confidence in positive clinical data for its CRISPR-based therapies, highlighting ongoing interest in gene editing.
- GeneDX's Disappointing Results: GeneDX's stock plummeted 49% after Q1 revenue grew only 17% to $102.3 million, falling short of the expected 30% growth, and the company lowered its 2026 revenue forecast to $475 million-$490 million, indicating significant business challenges ahead.
- Cathie Wood's Buying Strategy: Despite the negative market sentiment, Cathie Wood's Ark Invest increased its positions in Shopify, Intellia, and GeneDX during the downturn, suggesting her optimism about their long-term potential, which may attract other investors' attention.
See More
Intellia Announces HAELO Clinical Trial Data Presentation
- Clinical Trial Data Presentation: Intellia Therapeutics will present data from the HAELO clinical trial at the 2026 EAACI Annual Congress, indicating the potential of its CRISPR gene editing therapy, lonvo-z, to revolutionize treatment standards for hereditary angioedema (HAE).
- Key Presentation Schedule: The company is set to deliver an oral presentation on June 13, showcasing results from a global randomized double-blind trial, which is expected to garner significant attention and enhance Intellia's market position.
- Poster Presentation Focus: Additionally, Intellia will present a poster detailing the treatment barriers faced by HAE patients in Europe, aiming to raise awareness of the condition and promote better treatment options, potentially fostering future collaborations and research.
- Regulatory Recognition: Lonvo-z has received five notable regulatory designations, including Orphan Drug and RMAT designations from the FDA, highlighting its innovative potential in HAE treatment and likely providing significant market opportunities and investor confidence for the company.
See More
Buffett's Investment Strategy and Healthcare Opportunities
- Investment Legacy: Warren Buffett has led Berkshire Hathaway to market-beating returns over 60 years by focusing on industries and companies with competitive advantages, and new CEO Greg Abel has pledged to continue this investment philosophy.
- Healthcare Sector Absence: Despite a diverse portfolio, Berkshire Hathaway is almost entirely absent from the healthcare sector, holding only kidney care giant DaVita, which Buffett added in 2011, while Abel closed the position in UnitedHealth Group in Q1 this year.
- Healthcare Investment Opportunities: The healthcare industry offers a wide range of investment options, with aggressive investors potentially targeting high-growth pharmaceutical companies like Eli Lilly, while conservative investors may prefer dividend-paying companies like Johnson & Johnson and Abbott Laboratories for steady earnings growth.
- Independent Investment Decisions: While it is valuable to follow the investment decisions of Buffett and Abel, investors should also consider the high-potential healthcare sector and make independent investment choices to capitalize on growth opportunities in this field.
See More
Buffett and Abel's Investment Strategies
- Investment Legacy: Warren Buffett has led Berkshire Hathaway to market-beating returns over the past sixty years, and new CEO Greg Abel promises to continue this successful path, demonstrating stability and continuity in the company's leadership.
- Portfolio Analysis: Berkshire Hathaway's largest holding is Apple, and although Buffett typically avoids tech stocks, he opened a position in Alphabet last year, with Abel increasing it in Q1 this year, indicating a cautious interest in the tech sector.
- Healthcare Sector Absence: Despite a diverse portfolio, the healthcare sector is almost entirely absent, with only DaVita added in 2011, and Abel closing the position in UnitedHealth Group in Q1, reflecting a potential missed growth opportunity in this vital industry.
- Independent Investor Thinking: While Buffett and Abel's investment strategies are worth following, investors should make independent decisions based on their own needs and resources, as the healthcare sector offers diverse investment opportunities, particularly in biotech and pharmaceuticals, which could yield significant returns.
See More
FDA Issues Draft Guidance to Accelerate Gene Therapy Development
- Draft Guidance Release: The FDA has issued a draft guidance aimed at accelerating the R&D process for gene and cell therapies by leveraging existing scientific and regulatory knowledge, which is expected to significantly enhance the approval efficiency of therapeutic products.
- Streamlined Regulatory Submissions: The guidance will clarify how sponsors can utilize publicly available information and established platform knowledge, including chemistry, manufacturing, and controls (CMC) data, to simplify regulatory submissions for human gene therapy products, thereby reducing compliance costs for companies.
- Early Engagement Recommendations: The FDA encourages companies to engage with it before submitting an IND application, including participating in Initial Targeted Engagement for Regulatory Advice on CBER/CDER Products (INTERACT) and pre-IND meetings, to ensure their development plans align with regulatory expectations, thus increasing their chances of success.
- Significant Industry Impact: The release of this draft guidance is likely to have a positive impact on leading gene and cell therapy biopharma companies, such as CRISPR Therapeutics and Intellia Therapeutics, potentially accelerating their product launch timelines and fostering overall industry growth.
See More
Intellia Reports Positive Phase 3 Data for Lonvo-z, Plans U.S. Launch in 2027
- Clinical Trial Success: Intellia's Phase 3 HAELO trial demonstrated that a single infusion of lonvo-z reduced HAE attacks by 87%, highlighting its potential as an innovative treatment that could significantly enhance patient quality of life.
- Regulatory Application Progress: The company has initiated a rolling Biologics License Application (BLA) for lonvo-z, with plans to complete the submission in the second half of 2026, which, if approved, will provide a unique treatment option for HAE patients and further solidify Intellia's leadership in gene editing.
- Strong Financial Position: As of March 31, 2026, Intellia reported $517.2 million in cash and cash equivalents, and with the $207 million raised from the public offering in April, the company expects to fund operations through at least 2028, ensuring the market launch of lonvo-z.
- Clinical Trials Resumed: Intellia has resumed patient screening for the MAGNITUDE and MAGNITUDE-2 trials of nex-z, with plans to complete patient enrollment in the second half of 2026, further advancing the treatment landscape for ATTR amyloidosis.
See More
Shopify and Others Tumble as Cathie Wood Buys on Dip
- Shopify Earnings Performance: Shopify reported a 34% revenue increase to $102.3 million in Q1, driven by a 35% rise in GMV, but a cautious outlook led to a 16% stock drop, indicating market concerns over its high valuation.
- Intellia's Positive Outlook: Intellia Therapeutics saw only a 4% decline, with Canaccord raising its price target from $48 to $58, reflecting confidence in positive clinical data for its CRISPR-based therapies, highlighting ongoing interest in gene editing.
- GeneDX's Disappointing Results: GeneDX's stock plummeted 49% after Q1 revenue grew only 17% to $102.3 million, falling short of the expected 30% growth, and the company lowered its 2026 revenue forecast to $475 million-$490 million, indicating significant business challenges ahead.
- Cathie Wood's Buying Strategy: Despite the negative market sentiment, Cathie Wood's Ark Invest increased its positions in Shopify, Intellia, and GeneDX during the downturn, suggesting her optimism about their long-term potential, which may attract other investors' attention.
See More
